This clinical trial is focused on studying the effects of a medication called Tovinontrine in patients with chronic heart failure with preserved ejection fraction (HFpEF). Chronic heart failure is a condition where the heart is unable to pump blood effectively, and in this specific type, the heart’s pumping ability is preserved, but it still struggles to fill properly. The study will compare the effects of Tovinontrine, a small molecule inhibitor of phosphodiesterase type 9 (PDE9), with a placebo to understand its safety and effectiveness.

The purpose of the study is to evaluate how Tovinontrine affects levels of a substance in the blood called N-terminal pro b-type natriuretic peptide (NT-proBNP), which is often elevated in heart failure. Participants will be randomly assigned to receive either Tovinontrine or a placebo. The study will last for 12 weeks, during which participants will take the medication in tablet form by mouth. Throughout the study, various health assessments will be conducted to monitor changes in NT-proBNP levels and other health indicators.

This trial aims to provide valuable information on whether Tovinontrine can be a safe and effective treatment option for individuals with HFpEF. By understanding its impact on NT-proBNP levels and other health measures, researchers hope to find new ways to manage this challenging condition.